NCT05039281

Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma

Recruiting now Phase 1, PHASE2 Last updated 19 December 2025

What this trial tests

Phase 1, PHASE2 trial testing Atezolizumab in Recurrent Glioblastoma in 6 participants. Currently enrolling.

Timeline

23 September 2022

Primary endpoint
31 December 2027

31 December 2027

Quick facts

Lead sponsor	M.D. Anderson Cancer Center
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	6
Start date	23 September 2022
Primary completion	31 December 2027
Estimated completion	31 December 2027
Sites	1 location across United States

Drugs / interventions tested

• Atezolizumab (atezolizumab) — full drug profile →
• Cabozantinib (CABOZANTINIB) — full drug profile →

Conditions studied

• Recurrent Glioblastoma — all drugs for Recurrent Glioblastoma →
• Recurrent Gliosarcoma — all drugs for Recurrent Gliosarcoma →

Sponsor

M.D. Anderson Cancer Center — full company profile →

Who can join

18 and older, any sex, with Recurrent Glioblastoma or Recurrent Gliosarcoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This phase I/II trial tests the safety and side effects of atezolizumab in combination with cabozantinib and whether they work to shrink tumors in patients with glioblastoma that has come back (recurrent). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving atezolizumab and cabozantinib may help control the disease in patients with recurrent glioblastoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

1. Dissecting the Role of AXL in Cancer Immune Escape and Resistance to Immune Checkpoint Inhibition.
   Engelsen AST, Lotsberg ML, Abou Khouzam R, Thiery JP, et al · · 2022 · cited 74× · PMID 35572601 · DOI 10.3389/fimmu.2022.869676
2. Immunotherapeutic Strategies for the Treatment of Glioblastoma: Current Challenges and Future Perspectives.
   Salvato I, Marchini A. · · 2024 · cited 32× · PMID 38610954 · DOI 10.3390/cancers16071276
3. Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy.
   Petrazzuolo A, Maiuri MC, Zitvogel L, Kroemer G, et al · · 2022 · cited 23× · PMID 35655707 · DOI 10.1080/2162402x.2022.2077898
4. The Metabolic Orchestration of Immune Evasion in Glioblastoma: From Molecular Perspectives to Therapeutic Vulnerabilities.
   Medikonda R, Abikenari M, Schonfeld E, Lim M. · · 2025 · cited 17× · PMID 40507361 · DOI 10.3390/cancers17111881
5. Antiangiogenic Therapy for Malignant Brain Tumors: Does It Still Matter?
   Pellerino A, Bruno F, Soffietti R, Rudà R. · · 2023 · cited 17× · PMID 37071295 · DOI 10.1007/s11912-023-01417-1
6. c-MET and the immunological landscape of cancer: novel therapeutic strategies for enhanced anti-tumor immunity.
   Jabbarzadeh Kaboli P, Roozitalab G, Farghadani R, Eskandarian Z, et al · · 2024 · cited 12× · PMID 39664377 · DOI 10.3389/fimmu.2024.1498391
7. T Cell Features in Glioblastoma May Guide Therapeutic Strategies to Overcome Microenvironment Immunosuppression.
   Losurdo A, Di Muzio A, Cianciotti BC, Dipasquale A, et al · · 2024 · cited 12× · PMID 38339353 · DOI 10.3390/cancers16030603
8. Investigational treatment strategies in glioblastoma: progress made and barriers to success.
   Nelson TA, Dietrich J. · · 2023 · cited 11× · PMID 37796104 · DOI 10.1080/13543784.2023.2267982